Print this page
-
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-Stage Triple-Negative Breast Cancer.
Protocol: 042304Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
Protocol: 042305Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A First-in-Human Study of Mutant-selective PI3K alpha; Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Any Site
Liver
Other Digestive Organ -
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors.
Protocol: 052008Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Any Site -
A Dose Finding Study of CycloSam® (153Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewings Sarcoma, and other solid tumor(s) to the bone all eligible).
Protocol: 052201Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site
Breast
Lung
Prostate -
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and In Combination with Docetaxel in Subjects with Advanced MTAP-Null Solid Tumors.
Protocol: 052208Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase IA/IB, Open Label, Multicenter, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Protocol: 052212Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications.
Protocol: 052302Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
Protocol: 052305Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in
Subjects with Ovarian Cancer
Protocol: 052306Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Ovary -
A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
Protocol: 052308Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
Protocol: 052310Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and
Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult
Subjects with Advanced Solid Malignancies
Protocol: 052401Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors.
Protocol: 052402Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site